会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 42. 发明公开
    • IKK-β 억제제로서 신규 티아졸리디논 화합물 및 그의 제조방법
    • 新型噻唑烷酮化合物作为IKK-β 抑制剂及其制备方法
    • KR1020120035684A
    • 2012-04-16
    • KR1020100097362
    • 2010-10-06
    • 한국과학기술연구원
    • 남길수신계정배애님노은주추현아최경일정혜진김희숙
    • C07D277/24C07D417/06A61K31/427A61P19/02
    • PURPOSE: A thiazolidinone compound with IKK-beta suppression and a pharmaceutical composition containing the same are provided to prevent and treat rheumatoid arthritis, degenerative arthritis, asthma, and cancer. CONSTITUTION: A thiazolidine-4-one derivative is denoted by chemical formula 1. A pharmaceutical composition for treating inflammatory diseases or cancer contains the compound of chemical formula 1 as an active ingredient. The inflammatory diseases include rheumatoid arthritis, degenerative arthritis, asthma, or chronic obstructive lung diseases. A method for preparing the thiazolidione compound comprises: a step of cyclizing aryl thiourea compound of chemical formula 2 with ethyl 2-chloroacetate or prepare 2-arylimino-thiazolidine-4-one compound of chemical formula 3 or 4; a step of condensing the compound of chemical formula 3 or 4 with aryl aldehyde compound of chemical formula 5.
    • 目的:提供具有IKK-β抑制的噻唑烷酮化合物和含有它们的药物组合物以预防和治疗类风湿性关节炎,退行性关节炎,哮喘和癌症。 构成:噻唑烷-4-酮衍生物由化学式1表示。用于治疗炎性疾病或癌症的药物组合物含有化学式1的化合物作为活性成分。 炎性疾病包括类风湿性关节炎,退行性关节炎,哮喘或慢性阻塞性肺疾病。 制备噻唑烷二酮化合物的方法包括:用2-氯乙酸乙酯环化化学式2的芳基硫脲化合物或制备化学式3或4的2-芳基亚氨基 - 噻唑烷-4-酮化合物的步骤; 将化学式3或4的化合物与化学式5的芳基醛化合物缩合的步骤。
    • 47. 发明公开
    • 베타 아밀로이드 피브릴 형성 억제 화합물, 이의 제조 방법 및 이를 포함하는 약학 조성물
    • 用于BETA淀粉样纤维形成的抑制化合物及其制备方法和包含其的药物组合物
    • KR1020080022988A
    • 2008-03-12
    • KR1020060086900
    • 2006-09-08
    • 한국과학기술연구원한미사이언스 주식회사
    • 김동찬김동진유경호신계정변성림이관순김맹섭안영길묵인희
    • C07D213/34C07D213/26C07D213/30
    • C07D213/38C07D213/30
    • An inhibitory compound for formation of beta-amyloid fibril is provided to inhibit formation of senile plaque caused by beta-amyloid by specifically recognizing beta-amyloid without cytotoxicity and improve brain blood barrier(BBB) permeability, so that the compound is useful for treatment of degenerative brain disease containing dementia. A compound for inhibiting formation of beta-amyloid fibril represented by the formula(1) is prepared by performing Honer-Emmons reaction of compounds represented by the formula(2) with aldehyde compounds represented by the formula(3) and base such as metal hydrogen compound, metal alkoxide, alkyl alkali metal compound or amide type alkali metal compound in an organic solvent, wherein X is N or C; R^1 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy or C1-C3 alkylamino group; and R^2 and R^3 are each independently OH, p-methoxybenzyloxy(OPMB), C1-C3 alkoxy, NO2, NH2, C1-C3 alkyl amino or di C1-C3 alkyl amino. Further, the organic solvent is an ether typed organic solvent.
    • 提供用于形成β-淀粉样蛋白原纤维的抑制化合物,以通过特异性识别β-淀粉样蛋白而不具有细胞毒性并改善脑血管屏障(BBB)通透性,从而抑制由β-淀粉样蛋白引起的老年斑的形成,使得该化合物可用于治疗 退行性脑病包含痴呆症。 由式(1)表示的抑制β-淀粉样蛋白原纤维形成的化合物通过由式(2)表示的化合物与由式(3)表示的醛化合物和碱例如金属氢进行Hon-Emmons反应来制备 化合物,金属醇盐,烷基碱金属化合物或酰胺型碱金属化合物在有机溶剂中,其中X是N或C; R 1是H,卤素,C 1 -C 3烷基,C 1 -C 3烷氧基或C 1 -C 3烷基氨基; R 2和R 3各自独立地为OH,对甲氧基苄氧基(OPMB),C1-C3烷氧基,NO2,NH2,C1-C3烷基氨基或二C1-C3烷基氨基。 此外,有机溶剂是醚类有机溶剂。